Seastar Medical Holding Corporation ( (ICU) ) has released its Q2 earnings. Here is a breakdown of the information Seastar Medical Holding Corporation presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SeaStar Medical Holding Corporation is a commercial-stage healthcare company that focuses on developing innovative treatments for critically ill patients, particularly those facing organ failure. The company operates in the healthcare sector and is known for its Selective Cytopheretic Device (SCD) technology.
In its second quarter of 2025, SeaStar Medical reported significant advancements in its clinical trials and business operations. The company highlighted the enrollment of additional patients in its NEUTRALIZE-AKI trial, the adoption of its QUELIMMUNE therapy by new children’s hospitals, and positive survival results from its SAVE Surveillance Registry.
Key financial metrics revealed a net revenue of $0.3 million, primarily from sales of the QUELIMMUNE therapy. The company managed to reduce its research and development, as well as general and administrative expenses, compared to the previous year. SeaStar Medical also raised $12.4 million through public offerings to support ongoing operations.
Strategically, SeaStar Medical has achieved over 60% enrollment in its NEUTRALIZE-AKI trial and secured a $2 million grant from the Department of Defense for further research. The company is also focusing on expanding its customer base and enhancing its financial position through cost-saving measures.
Looking ahead, SeaStar Medical aims to achieve key milestones, including interim results from its NEUTRALIZE-AKI trial and further expansion of its QUELIMMUNE therapy. The management remains optimistic about filing for Pre-Marketing Approval for its SCD therapy in 2026, potentially transforming treatment options for adult patients with Acute Kidney Injury.